**SUPPLEMENTAL DATA**

**Table A : Recommendations for antiretrovirals in pregnancy according to successive French national guidelines.** 1: Treatment recommended as first-line**;** 2: Alternative**;** 3: Not recommended: contraindication or insufficient data in pregnancy to recommend

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 2004 | 2006 | 2008 | 2010 | 2013 |
| **NRTIa** |  |  |  |  |  |
| Zidovudine | 1 | 1 | 1 | 1 | 1 |
| Didanosine | 2\* | 1\* | 2\* | 2 | 3 |
| Lamivudine | 1 | 1 | 1 | 1 | 1 |
| Stavudine | 2\* | 2\* | 2\* | 3 | 3 |
| Abacavir | 2 | 2 | 2 | 2 | 1 |
| Tenofovir | 3 | 3 | 3 | 2 | 1 |
| Emtricitabine | 3 | 3 | 3 | 2 | 1 |
| **NNRTIb** |  |  |  |  |  |
| Nevirapine | 3 | 2\*\* | 2\*\* | 2\*\* | 2\*\* |
| Delavirdine | 3 | 3 | 3 | 3 | 3 |
| Efavirenz | 3 | 3 | 3 | 3 | 3 |
| Etravirine | 3 | 3 | 3 | 3 | 3 |
| Rilpivirine | 3 | 3 | 3 | 3 | 3 |
| **Protease inhibitors** |  |  |  |  |  |
| Amprenavir | 3 | 3 | 3 | 3 | 3 |
| Ritonavir | 1 | 1 | 1 | 1 | 1 |
| Saquinavir | 1 | 1 | 1 | 1 | 2 |
| Nelfinavir | 1 | 1 | 3 | 3 | 3 |
| Indinavir | 3 | 2 | 2 | 2 | 3 |
| Lopinavir | 3 | 1 | 1 | 1 | 1 |
| Atazanavir | 3 | 3 | 3 | 2 | 1 |
| Fosamprenavir | 3 | 2 | 2 | 2 | 3 |
| Tipranavir | 3 | 3 | 3 | 3 | 3 |
| Darunavir | 3 | 3 | 3 | 2 | 1 |
| **Integrase inhibitors** |  |  |  |  |  |
| Raltegravir | - | - | 3 | 2\*\*\* | 2\*\*\* |
| Elvitegravir | - | - | - | - | - |
| Dolutegravir | - | - | - | - | - |
| **Others** |  |  |  |  |  |
| Maraviroc | 3 | 3 | 3 | 3 | 3 |
| Enfurvitide | 3 | 3 | 2\*\*\* | 2\*\*\* | 2\*\*\* |

a NRTI : Nucleoside reverse transcriptase inhibitors

b NNRTI : Non nucleoside reverse transcriptase inhibitors

\* contra-indicated in association with D4T

\*\*acceptable if started before the pregnancy

\*\*\* recommended in case of virologic rebound or late presenter

**Table B : Univariate and multivariate associations between virological rebound and the type of treatment according to guidelines in HIV+ pregnant women on ART viral suppression at the conception who changed ART in the first trimester for safety concerns (EPF-CO1. 2005-2015)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | |  |  | Virological rebound (VL > 50 cp/mL) | | | | | | | | | | | | | | | | | | | | | | | | | |
| **N** | **During the pregnancy** | | | | | | | |  | | **Near delivery** | | | | | | | | | | | | | | | | |
| **%** | **Univariate Analysis** | | | | **Multivariate Analysis** | | | | | **%** | **Univariate Analysis** | | | | | | **Multivariate Analysis** | | | | | | | | | |
| **HR** | **IC 95%** | **p** |  | **HRa** | | **IC 95%** | | **p** | **OR** | | **IC 95%** | | **p** | | **ORa** | | **IC 95%** | | | **p** | |
| Type of treatment according to the guidelines | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Recommended | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | Change | | 25 | 8 | 0.4 | [0.0-2.7] | .3 |  | 0.4 | [0.0-2.9] | | | .4 | 4.0 | | 1.0 | | [0.1-8.1] | | 1 | | 1.2 | | [0.1-9.4] | | | .9 | |
|  | No change | | 387 | 15.3 | 1 |  |  |  | 1 |  | | |  | 3.9 | | 1 | |  | |  | | 1 | |  | | |  | |
| Alternative | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | Change | | 71 | 27.5 | 1.7 | [0.9-3.1] | .1 |  | 1.6 | [0.9-2.9] | | | .2 | 4.5 | | 1.1 | | [0.3-3.8] | | .8 | | 1.1 | | | [0.3-3.7] | | .9 | | |
|  | No change | | 667 | 14.3 | 1 |  |  |  | 1 |  | | |  | 4.0 | | 1 | |  | |  | | 1 | | |  | |  | | |
| Not recommended | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | Change | | 315 | 18.4 | 0.9 | [0.6-1.3] | .5 |  | 0.9 | [0.6-1.4] | | | .6 | 7.1 | | 1.1 | | [0.6-2.0] | | .8 | | 1.1 | | | [0.6-2.1] | | .8 | | |
|  | | No change | 355 | 18.7 | 1 |  |  |  | 1 |  | | |  | 6.7 | | 1 | |  | |  | | 1 | | |  | |  | | |

OR: crude odd ratio, ORa: odd ratio adjusted on the propensity score , HR: crude hazard ratio, HRa: hazard ratio adjusted on the propensity score. 1Logistic regression, 2Cox model

**Table C : Associations between switch and virologic rebound in women with a viral load <50 copies/mL who changed efavirenz in the first trimester as a safety concerns to follow guidelines patients. Uni and multivariate analysis by survival analysis or logistic regression (EPF-CO1. 2005-2015)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Switch EFV | | | |  | Univariate analysis | | |  | Multivariate analysis | | |
| **No (N=1364)** | | **Yes (N=143)** | |  | **OR1 /HR2** | **IC 95%** | **p** |  | **ORa1 /HRa2** | **IC 95%** | **p** |
| **n** | **%** | **n** | **%** |  |  |
| Virological rebound (VL > 50 cp/mL) | | | | | | | | | | | | |
| During the pregnancy | 212 | 15.6 | 24 | 16.8 |  | 1.3**2** | [0.8-2.0] | 0.3 |  | 1.1**2**a | [0.7-1.8] | 0.7 |
| Near delivery | 58 | 4.6 | 11 | 8.3 |  | 1.9**1** | [0.9-3.6] | 0.07 |  | 1.8**1**a | [0.9-3.6] | 0.1 |

aajustement on the propensity score

VL : viral load, OR: crude odd ratio, ORa: odd ratio adjusted on the propensity score , HR: crude hazard ratio, HRa: hazard ratio adjusted on the propensity score. 1Logistic regression, 2Cox mode